M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic or anaphylactoid reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; an immunodeficient condition or receiving immunosuppressive therapy; an active febrile illness; or those who are pregnant.

Due caution should be employed in administration of M-M-R®II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided.

The following adverse reactions have been reported with M-M-R®II without regard to causality: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, and thrombocytopenia.

As for any vaccine, vaccination with M-M-R®II may not result in protection in 100% of vaccinees.

M-M-R®II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

VACC-1159574-0001 05/16

Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases. Vaccine Storage & Handling Toolkit. http://www.cdc.gov/vaccines/recs/storage/toolkit/storage-handling-toolkit.pdf. Published May 2014. Accessed February 29, 2016.

Food and Drug Administration (FDA). Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of ProQuad™. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123800.pdf. Effective August 26, 2005. Accessed February 29, 2016.

Food and Drug Administration (FDA). Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of ProQuad™. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123800.pdf. Effective August 26, 2005. Accessed February 29, 2016.

Food and Drug Administration (FDA). Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of ProQuad™. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123800.pdf. Effective August 26, 2005. Accessed February 29, 2016.